Effects of the cardiac myosin activator Omecamtiv-mecarbil on severe chronic aortic regurgitation in Wistar rats
Abstract Background Aortic regurgitation (AR) is a valvular disease that can lead to systolic heart failure. Treatment options besides cardiac surgery are limited and consequently severe AR is associated with higher mortality and morbidity when not operated. In this investigation, we examined the ef...
Main Authors: | Bachar El-Oumeiri, Kathleen Mc Entee, Filippo Annoni, Antoine Herpain, Frédéric Vanden Eynden, Pascal Jespers, Guido Van Nooten, Philippe van de Borne |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-05-01
|
Series: | BMC Cardiovascular Disorders |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12872-018-0831-3 |
Similar Items
-
The myosin activator omecamtiv mecarbil improves wall stress in a rat model of chronic aortic regurgitation
by: Bachar El Oumeiri, et al.
Published: (2021-08-01) -
Altered Left Ventricular Rat Gene Expression Induced by the Myosin Activator Omecamtiv Mecarbil
by: Bachar El Oumeiri, et al.
Published: (2023-01-01) -
Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil
by: Edgardo Kaplinsky, et al.
Published: (2018-04-01) -
Safety and efficacy of omecamtiv mecarbil for heart failure: A systematic review and meta-analysis
by: Fadel Alqatati, et al.
Published: (2022-05-01) -
Omecamtiv mecarbil in precision-cut living heart failure slices: A story of a double-edged sword
by: Jorik H. Amesz, et al.
Published: (2023-09-01)